ab17041 ACP5 Antibody

ab17041 at 1/100 staining Human ovarian cancer by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the primary antibody at 4°C overnight. An HRP conjugated anti-Rabbit antibody was used as the secondary antibody.

Figure 4. |rSj‑Cys inhibits the expression of osteoclastogenesis‑related genes and proteins. RAW264.7 cells were co‑stimulated with M‑CSF (25 ng/ml) and RANKL (30 ng/ml) and then treated with or without rSj‑Cys (0.3 µM) for different time periods (24, 48 or 72 h). The expression levels of genes and proteins associated with osteoclast phenotype markers (CTSK, TRAP, ITGB3) and cell surface receptors of osteoclast precursors (RANK, OSCAR, TREM‑2)were determined by (A) reverse transcription‑quantitative PCR and (B) western blot analysis.

Figure 3 TsI restrains osteoclastogenesis in the femoral heads of the MPS-induced SIONFH rat model. (a) TRAP activity in the serum. (b) Expression levels of CTSK and ACP5 in the femoral heads. ∗∗p < 0.01; ns, no significant. TRAP, tartrate-resistant acid phosphatase; CTSK, cathepsin K; ACP5, acid phosphatase 5.